NOS2 and neoplasm: As mentioned throughout this review, recognition of iNOS/NO signaling for a survival, proliferative, and migratory advantage in tumor cells is often based on the mitigating effects of specific iNOS activity inhibitors (1400W and GW274150) or a NO scavenger (cPTIO).